| scholarly article | Q13442814 |
| meta-analysis | Q815382 |
| P356 | DOI | 10.1016/S2213-8587(14)70213-X |
| P698 | PubMed publication ID | 25466239 |
| P2093 | author name string | Ben Vandermeer | |
| Scot H Simpson | |||
| Ahmed S Abdelmoneim | |||
| Travis R Featherstone | |||
| Jayson Lee | |||
| Sabina Choi | |||
| P2860 | cites work | Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement | Q21562278 |
| Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). | Q22241288 | ||
| Cardiovascular outcomes in trials of oral diabetes medications: a systematic review | Q22253058 | ||
| Sulphonylurea monotherapy for patients with type 2 diabetes mellitus | Q24197884 | ||
| National trends in treatment of type 2 diabetes mellitus, 1994-2007 | Q24619979 | ||
| The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions | Q27860564 | ||
| Meta-analysis in clinical trials | Q27860779 | ||
| Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group | Q27860882 | ||
| Meta-analysis of Observational Studies in Epidemiology: A Proposal for Reporting | Q27861077 | ||
| Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin | Q28236207 | ||
| GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients | Q28276621 | ||
| A Systematic Review and Meta-Analysis of Hypoglycemia and Cardiovascular Events: A comparison of glyburide with other secretagogues and with insulin | Q29397208 | ||
| Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes | Q29547541 | ||
| Effects of intensive glucose lowering in type 2 diabetes | Q29547736 | ||
| Combination of direct and indirect evidence in mixed treatment comparisons | Q29619499 | ||
| Glibenclamide-related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study | Q33508039 | ||
| Evaluation of inconsistency in networks of interventions | Q33620679 | ||
| The Bypass Angioplasty Revascularization Investigation 2 Diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: impact of treatment strategy on cardiac mortality and [...] | Q33696402 | ||
| The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: a retrospective analysis | Q33873053 | ||
| Tissue-specific effects of sulfonylureas: lessons from studies of cloned K(ATP) channels | Q34044365 | ||
| Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial | Q34985342 | ||
| Parachute approach to evidence based medicine | Q35060383 | ||
| Preconditioning: a paradigm shift in the biology of myocardial ischemia | Q35622752 | ||
| Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: a meta-analysis of observational studies | Q36807402 | ||
| Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl): a double-blind comparison with glibenclamide | Q36831661 | ||
| Preconditioning and postconditioning: new strategies for cardioprotection. | Q36933844 | ||
| Effect of second-generation sulfonylureas on survival in patients with diabetes mellitus after myocardial infarction | Q37148331 | ||
| Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. | Q37888895 | ||
| Variations in tissue selectivity amongst insulin secretagogues: a systematic review | Q37933466 | ||
| Association of sulphonylurea treatment with all-cause and cardiovascular mortality: a systematic review and meta-analysis of observational studies | Q38071847 | ||
| Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial | Q38085534 | ||
| Sulphonylureas and risk of cardiovascular disease: systematic review and meta-analysis | Q38105641 | ||
| The proarrhythmic effect of hypoglycemia: evidence for increased risk from ischemia and bradycardia | Q38161347 | ||
| Glyburide increases risk in patients with diabetes mellitus after emergent percutaneous intervention for myocardial infarction--a nationwide study | Q38443271 | ||
| Adverse cardiovascular events during treatment with glyburide (glibenclamide) or gliclazide in a high-risk population | Q39565271 | ||
| Sulphonylurea-metformin combination therapy, cardiovascular disease and all-cause mortality: the Fremantle Diabetes Study | Q39942752 | ||
| The Effects of Long-term Therapy with Oral Hypoglycemic Agents on the Oral Glucose Tolerance Test Dynamics in Male Chemical Diabetics | Q40772592 | ||
| Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs | Q41082502 | ||
| Do sulfonylurea drugs increase the risk of cardiac events? | Q41142080 | ||
| Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial | Q42672645 | ||
| Changes in body composition after 9 months of treatment with exenatide twice daily versus glimepiride: comment letter on Jendle et al. | Q42846843 | ||
| Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials. | Q43409321 | ||
| Type 2 diabetes mellitus management in Canada: is it improving? | Q43464962 | ||
| Risk of acute coronary events associated with glyburide compared with gliclazide use in patients with type 2 diabetes: a nested case-control study | Q43901204 | ||
| Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality | Q44205053 | ||
| Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes | Q44231053 | ||
| Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring | Q44418824 | ||
| All-cause mortality in diabetic patients treated with combinations of sulfonylureas and biguanides | Q44737943 | ||
| Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study | Q44802551 | ||
| Use patterns of antidiabetic regimens by patients with type 2 diabetes | Q45896670 | ||
| Trends in the prescription of anti-diabetic medications in the United Kingdom: a population-based analysis. | Q45924271 | ||
| Sulfonylureas and prognosis after myocardial infarction in patients with diabetes: a population-based follow-up study. | Q46002806 | ||
| The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial. | Q46835037 | ||
| Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin | Q46981921 | ||
| Comparison of two sulfonylureas with high and low myocardial K(ATP) channel affinity on myocardial infarct size and metabolism in a rat model of type 2 diabetes | Q47404089 | ||
| Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. | Q50535464 | ||
| Effects of antihyperglycaemic therapies on proinsulin and relation between proinsulin and cardiovascular risk factors in type 2 diabetes. | Q51550632 | ||
| Pharmacologic management of type 2 diabetes. | Q54273345 | ||
| Risk and Short-Term Prognosis of Myocardial Infarction Among Users of Antidiabetic Drugs | Q57300672 | ||
| Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool | Q57542870 | ||
| Mortality outcomes of different sulphonylurea drugs: the results of a 14-year cohort study of type 2 diabetic patients | Q59650477 | ||
| Effects of gliclazide on platelet reactivity and free radicals in type II diabetic patients: Clinical assessment | Q61831256 | ||
| Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: a retrospective analysis | Q63966646 | ||
| The risk of overall mortality in patients with Type 2 diabetes receiving different combinations of sulfonylureas and metformin: a retrospective analysis | Q63966651 | ||
| Comparison of gliclazide and glibenclamide treatment in non-insulin-dependent diabetes | Q70512305 | ||
| Blood Sugar Lowering Effects of Chlorpropamide and Tolbutamide: A Double Blind Cooperative Study | Q71158862 | ||
| Network meta-analysis for indirect treatment comparisons | Q74720205 | ||
| Increased QT dispersion during hypoglycaemia in patients with type 2 diabetes mellitus | Q78216138 | ||
| Sulfonylureas and the risk of myocardial infarction | Q83188094 | ||
| Antidiabetic treatments and risk of hospitalisation with myocardial infarction: a nationwide case-control study | Q83731087 | ||
| 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial | Q84502143 | ||
| P433 | issue | 1 | |
| P921 | main subject | meta-analysis | Q815382 |
| systematic review | Q1504425 | ||
| P304 | page(s) | 43-51 | |
| P577 | publication date | 2014-10-22 | |
| P1433 | published in | The Lancet: Diabetes & Endocrinology | Q27725107 |
| P1476 | title | Mortality risk among sulfonylureas: a systematic review and network meta-analysis | |
| P478 | volume | 3 |
| Q38340187 | Antidiabetic therapy in post kidney transplantation diabetes mellitus. |
| Q89478072 | Association of glucose-lowering medications with cardiovascular outcomes: an umbrella review and evidence map |
| Q28067085 | Bringing patient centricity to diabetes medication access in Canada |
| Q57093598 | Cardiovascular Safety of Antihyperglycemic Agents: "Do Good or Do No Harm" |
| Q39420208 | Cardiovascular disease prevention strategies for type 2 diabetes mellitus |
| Q31143283 | Cardiovascular events and all-cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: A Bayesian meta-analysis of survival data |
| Q37620904 | Cardiovascular safety of non-insulin pharmacotherapy for type 2 diabetes |
| Q38364806 | Cardiovascular safety of sulphonylureas: over 40 years of continuous controversy without an answer. |
| Q50043733 | Comparative Safety of Sulfonylureas and the Risk of Sudden Cardiac Arrest and Ventricular Arrhythmia |
| Q33727891 | Comparative effectiveness of oral antidiabetic drugs in preventing cardiovascular mortality and morbidity: A network meta-analysis |
| Q61801321 | Comparative effectiveness of the different components of care provided in heart failure clinics-protocol for a systematic review and network meta-analysis |
| Q38644587 | Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas. |
| Q50126677 | Diabetes in the older patient: heterogeneity requires individualisation of therapeutic strategies. |
| Q37101613 | Diabetes treatments and risk of heart failure, cardiovascular disease, and all cause mortality: cohort study in primary care |
| Q51744921 | Do sulphonylureas still have a place in clinical practice? |
| Q40787120 | Dose-response relationship between sulfonylureas and major adverse cardiovascular events in elderly patients with type 2 diabetes |
| Q39427199 | Effects of glucose-lowering agents on ischemic stroke |
| Q47691659 | Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial |
| Q36820255 | Glucose-lowering therapy in type 2 diabetes. New hope after the EMPA-REG outcome trial |
| Q38899869 | Hypoglycaemia when adding sulphonylurea to metformin: a systematic review and network meta-analysis. |
| Q38524435 | Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes |
| Q38754132 | Is gliclazide a sulfonylurea with difference? A review in 2016. |
| Q33790423 | Large-scale pharmacogenomic study of sulfonylureas and the QT, JT and QRS intervals: CHARGE Pharmacogenomics Working Group. |
| Q99623034 | Modern sulphonylureas and cardiovascular adverse effects: Will CAROLINA put an end to the controversy? |
| Q38962521 | No increased risk of cardiovascular events in older adults initiating dipeptidyl peptidase-4 inhibitors vs therapeutic alternatives. |
| Q41767426 | Not All Diabetes in Infants is Type 1: A Case Report |
| Q26783199 | Place of sulfonylureas in the management of type 2 diabetes mellitus in South Asia: A consensus statement |
| Q48177243 | Potential Applications of Gliclazide in Treating Type 1 Diabetes Mellitus: Formulation with Bile Acids and Probiotics. |
| Q30234356 | Pro- and Antiarrhythmic Actions of Sulfonylureas: Mechanistic and Clinical Evidence |
| Q26748870 | The Association between Sulfonylurea Use and All-Cause and Cardiovascular Mortality: A Meta-Analysis with Trial Sequential Analysis of Randomized Clinical Trials |
| Q47733021 | The Infamous, Famous Sulfonylureas and Cardiovascular Safety: Much Ado About Nothing? |
| Q64248091 | The Standard of Care in Type 2 Diabetes: Re-evaluating the Treatment Paradigm |
| Q58447602 | Type 2 diabetes mellitus |
Search more.